With melittin treatment, the percentage of CD11b+F4/80+ macrophages in CD45+ tumor infiltrating leukocytes was significantly decreased (63.25 ± 5.34 for control vs. 38.70 ± 0.79 for melittin) (Figure 3B). The gene discussed is PTPRC; the disease is neoplasm.